Institute of Clinical Pharmacology and Toxicology, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Br J Clin Pharmacol. 2010 Aug;70(2):164-70. doi: 10.1111/j.1365-2125.2010.03672.x.
The considerable variability in the warfarin dose-response relationship between individuals, is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (VKORC1) enzymes. Despite the predominance of pharmacogenetics, environmental factors also affect the pharmacokinetics and pharmacodynamics of warfarin, and are often overlooked. Among these factors, dietary and supplemental vitamin K consumption is a controllable contributor to within-, and between-patient variability of warfarin sensitivity. In this commentary we review the current role of vitamin K in warfarin anticoagulation therapy, with emphasis on the following: 1 The effect of dietary and supplemental vitamin K on warfarin anticoagulation, beyond the impact of genetic variability in CYP2C9 and VKORC1. We deal separately with the effects of vitamin K on warfarin dose requirements during the induction of therapy, as opposed to its effect on stability of anticoagulation control during maintenance therapy. 2 The role of vitamin K supplementation in warfarin treated patients with vitamin K deficiency as well as in patients with unstable warfarin anticoagulation, and 3 The role of therapeutic vitamin K in cases of warfarin over-anticoagulation.
个体间华法林剂量反应关系存在较大差异,主要归因于其主要代谢(CYP2C9)和靶标(VKORC1)酶的遗传变异。尽管药物遗传学占主导地位,但环境因素也会影响华法林的药代动力学和药效学,且常被忽视。在这些因素中,饮食和补充维生素 K 的摄入是导致华法林敏感性个体内和个体间差异的可控因素。在本述评中,我们回顾了维生素 K 在华法林抗凝治疗中的当前作用,重点关注以下内容:1. 饮食和补充维生素 K 对华法林抗凝作用的影响,超出了 CYP2C9 和 VKORC1 遗传变异的影响。我们分别探讨了维生素 K 对治疗诱导期间华法林剂量需求的影响,以及其对维持治疗期间抗凝控制稳定性的影响。2. 维生素 K 补充在维生素 K 缺乏的华法林治疗患者以及华法林抗凝不稳定患者中的作用,以及 3. 治疗性维生素 K 在华法林抗凝过度患者中的作用。